Page 14 - emap_newsletter_V2

eMAP – electronic EHA Medical HemAtology Program

The most frequent TEAEs were thrombocytopenia (100%), anemia (90%), neutropenia (87%), and CRS (90%), with the most
common grade =3 TEAEs including thrombocytopenia (100%), neutropenia (69%), and anemia (52%). There were no grade =3
CRS events. Tocilizumab was administered in 74% of patients and corticosteroids administered in 10% of patients to manage
CRS. No neurological events were reported. Furthermore, 24 out of 28 eligible patients (86%) received the second/booster
dose after four months, with no CRS or neurotoxicity reported. About 25% of patients improved their response after reinfusion.

The study authors concluded that ARI0002h, an academic humanized CAR T cell therapy against BCMA, demonstrated deep
and durable responses with a favourable safety profile in RRMM patients.

WATCH WATCH
DR. REECE’S IN-DEPTH PRESENTATION OF THIS DR. REECE’S THOUGHTS ON THE RELEVANCE OF
ABSTRACT (~9 MINUTES) THESE DATA TO CANADIAN PRACTICE (~2 MINUTES)

CLICK HERE FOR THE LINK TO THE FULL ABSTRACT

ADDITIONAL ABSTRACTS OF INTEREST

The following is a list of additional abstracts related to cellular therapy and immunotherapy from the EHA 2022 Congress that
may be of interest. We invite the reader to explore these abstracts by clicking the links provided.

Cellular and Immunotherapies (CAR T cells, CELMoDs, bispecifics, etc.) for B-cell Lymphoma

Abstract # Abstract title

S212 PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED
USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

S214 PHASE 1/2 STUDY OF ANBAL-CEL, NOVEL ANTI-CD19 CAR-T THERAPY WITH DUAL SILENCING OF PD-1
AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA

S216 CLINICAL ACTIVITY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS
(PTS) WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE 1,
OPEN-LABEL STUDY

S219 FIRST CLINICAL STUDY OF THE ANTI-SIGNAL REGULATORY PROTEIN-ALPHA (SIRP?) ANTIBODY CC-
95251 COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN
LYMPHOMA (NHL)

S220 GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS
WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND =2 PRIOR THERAPIES: PIVOTAL
PHASE II EXPANSION RESULTS

TABLE OF CONTENTS 14